CYBIN CEO Doug Drysdale On How CYB-003 Is Better Than Psilocybin | Next Gen Psychedelics
In this episode of the Spotlight On, James Hallifax from…
Author: Psychedelic Spotlight
Daniel Carcillo On Psychedelics For TBI, Wesana Partnering With MAPS & Mike Tyson Collaboration
During our time at Wonderland Miami, $PSYC CEO, David Flores,…
We NEED to Talk about the Compass Pathways Psilocybin-for-Depression Trial Results: A WIN for CMPS??
In today’s episode, we discuss the results of the much awaited phase 2b clinical trial using psilocybin (comp360) to treat treatment-resistant-depression. This Compass Pathways (Nasdaq: CMPS) trial is so important for a couple of reasons: first, it is the largest ever psychedelics clinical trial, with 219 people completing the trial; and second because it is the furthest progressed psilocybin trial ever, being in phase 2b.
So what did the results say? Can Magic Mushrooms treat depression? Can Psychedelics help Mental Health?
Well, the results are mixed. About a quarter of the people who underwent Compass Pathways psychedelic therapy program, who received 25 mg of psilocybin (Comp 360), entered remission after 12 weeks. And almost a third of individuals in this group saw their depression symptoms decrease by 50% or more, as measured by the MADRS scale. This is more than double the success rate for the control group, showing strong significant effects of psilocybin therapy on depression. Therefore, it is clear that psychedelics like psilocybin CAN help mental health… at least somewhat
However, many, myself included, were hoping for stronger results, such as the MDMA to treat PTSD phase 3 results that MAPS released earlier this year. This led to disappointment at the positive results, as they were not as game changing as we had hoped.
In this episode, we describe Compass Pathways’ psilocybin for depression clinical trial, explain the results, and then try to put said results into context. We finish by looking towards the future, and discussing where Compass Pathways, and other psychedelic medicines companies like MindMed, Cybin and Small Pharma, should go from here.
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Links:
Compass Results: https://ir.compasspathways.com/static-files/0f9fbce8-2619-438b-a6ba-5bbe2ba08cf6
Montgomery-Asberg Depression Rating Scale (MADRS):
https://en.wikipedia.org/wiki/Montgomerysberg_Depression_Rating_Scale
MAPS MDMA-PTSD Study:
https://www.nytimes.com/2021/05/03/health/mdma-approval.html
Comp 360 Open Label Study:
https://www.globenewswire.com/en/news-release/2021/10/20/2317456/0/en/Open-label-study-of-COMP360-psilocybin-therapy-for-depression-in-cancer-patients-demonstrates-feasibility-of-simultaneous-psilocybin-administration-in-small-groups.html
MindMed Psilocybin SSRI Study:
https://mindmed.co/news/press-release/mindmed-and-liechti-lab-provide-results-from-their-psilocybin-rd-collaboration/
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#CompassPathways #psilocybin #depression
Interview with Sa’ad Shah, Managing Partner at Noetic Fund
In our conversation, Sa’ad gives us an overview of how his interest in philosophy led to his involvement with plant medicine, how the psychedelic industry is currently misunderstood and under appreciated, Noetic’s portfolio selection process, and more!
Atai Life Sciences, Compass Pathways, MindMed & Cybin’s Q3 Financial Results Analysis – What’s Next?
Analyzing the Quarter 3 financial results of atai Life Sciences (Nasdaq: ATAI), Compass Pathways (Nasdaq: CMPS), MindMed (Nasdaq: MNMD) and Cybin (NYSE: CYBN).
It’s earning season! In this episode we compare and contrast the financials of the four biggest companies in the psychedelic medicines space, atai, Compass Pathways, MindMed and CYBIN. All four released their Q3 financials in the past week. All four are the biggest psychedelic stocks
We also look at some of the highlights of the past quarter for each company, and do some rough back of the napkin math to determine when they will need to raise more capital.
Atai Life Sciences (atai stock) is the best financed company, and had a very eventful quarter. They started clinical trials studying r-ketamine, ibogaine, a schizophrenia drug and more.
Compass Pathways (CMPS stock), the next best financed psychedelics company, released the results of their long awaited Comp 360 phase 2b clinical trial, testing treating Treatment-Resistant Depression with psilocybin. They also announced a new trial using comp 360 to treat PTSD, hired the famous Hamilton Morris, and acquired an IP portfolio of novel medicines.
MindMed (MNMD Stock) had a quieter quarter, though it was still impressive. Despite having over a hundred million dollars in the bank, since they are spending so much on their million projects, they will likely have to raise capital through dilution within a year. Their work with LSD, 18-MC Psilocybin and more continues in the background, but this quarter was all about hiring talent.
Cybin (CYBN stock) is in a bigger cash crunch, only having enough capital for roughly a year. This means they will almost certainly be raising capital soon. Despite this, they had a great quarter and announced that their lead drug candidate CYB-003, a modified version of psilocybin, shows great promise in animal models.
Links:
Atai: https://www.atai.life/2021/11/05/atai-life-sciences-reports-third-quarter-2021-financial-results-and-corporate-update/
Compass Pathways: https://compasspathways.com/financial-results-and-business-highlights-for-the-third-quarter-2021/
MindMed:
https://www.prnewswire.com/news-releases/mindmed-announces-financial-results-for-the-third-quarter-2021-and-business-highlights-cash-balance-of-145-9-usd-185-4-cad-to-execute-on-diverse-clinical-pipeline-301423844.html
Cybin:
https://www.businesswire.com/news/home/20211115005552/en/Cybin-Inc.-Reports-its-Second-Quarter-Financial-Results-and-Recent-Business-Highlights
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#ataiLifeSciences #MindMed #Cybin
Compass Pathways launching NEW Phase II Clinical Trial to Treat PTSD!!!
Compass Pathways is launching a NEW Phase II clinical trial to treat PTSD!!!
The trial will use Comp 360, the company’s synthetic, proprietary version of psilocybin, in conjunction with therapy. This is Compass’ second major trial using Comp 360. They also are using it to treat Treatment Resistant Depression.
On October 3rd, 2021, Compass Pathways (Nasdaq: CMPS) announced the launch of a brand new psychedelic therapy clinical trial, using Psilocybin, the active ingredient in magic mushrooms, to treat PTSD.
The Phase 2 clinical trial will use Comp 360, Compass Pathways’ proprietary, synthetic, cristalline Psilocybin. It will be paired with talk psychotherapy in 20 adults who suffered trauma as an adult, resulting in PTSD.
While using psychedelics for mental health may seem controversial, when it comes to the science, psychedelics like psilocybin and MDMA, when paired with therapy have been shown to work.
For example, recently MAPS completed a Phase III clinical trial using MDMA therapy to treat PTSD, which showed 67% of people improving so much they no longer qualified to be diagnosed as having PTSD (cured?). Another 21% of people improved significantly.
This Compass Pathways trial is exciting, because once it is complete, we will be able to compare the results of their psilocybin trial to MAPS’ MDMA trial, to start to have an understanding of which psychedelic compound works better for treating PTSD.
This news comes as we are waiting for the results of Compass Pathways’ Phase 2b Clinical Trial, testing treating Treatment-Resistant Depression with Comp 360, to be released before the end of the year.
The results of the trial will be significant, as it will be the largest ever clinical trial studying psychedelics, with 216 patients. It will also be the most advanced clinical trial studying psilocybin, being in phase 2b.
In sum, these are very exciting times to be watching Compass Pathways. Controversies surrounding their patents aside, Compass is one of the companies pushing the frontiers of psychedelic medicines, which is very exciting to watch.
Do you think psilocybin assisted therapy could treat PTSD? Let us know in the comments.
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#CompassPathways #Psychedelics #CMPS
Interview with Awais Spall, Functional Diagnostic Nutrition Practitioner at Integrative Oasis
In this conversation, we discuss some critical points such as how he managed to heal himself through the use of Ayurveda and functional medicine which led him down the path to working with these interesting modalities, how ancestral healing has the ability to significantly influence an individual’s wellbeing overall, how his practice uses entheogens to cure physical ailments such as Traumatic Brain Injury, and more!
NEW MindMed MDMA trials, Compass Pathways Patent, Small Pharma DMT Trials Begins | MNMD, CMPS, DMT
NEW MindMed MDMA trials, Compass Pathways Patent, Small Pharma DMT Trials Begins | MNMD, CMPS, DMT
What’s up psychedelic investors! We have been seeing a lot of red in the last few months. Companies like MindMed (MNMD: NASDAQ) (MMED:NEO), Compass Pathways (CMPS: NASDAQ) &Small Pharma ( OTC: DMTTF) ( CVE: DMT) have had huge news in the last week. So in this episode we’ll be covering the major news surrounding these psychedelic stocks!
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #CompassPathways #PsychedelicStocks
Interview with Zoe Helene, Founder of Cosmic Sister
In our conversation, we discuss some of Zoe’s formative experiences in the creative arts which led her down the path of plant medicine advocacy, core feminist issues and how psychedelics play a role in furthering women’s movements, why an emphasis on equity and representation within the budding psychedelic industry is crucial and still has a long way to go, and so much more.
A NEW Psilocybin-Depression Study Was Just Released: The Results Are BREATHTAKING | GAME OVER?🚀🍄
A NEW Psilocybin-Depression Study Was Just Released: The Results Are BREATHTAKING | GAME OVER?🚀🍄
Hello Psychedelic Investors! It’s an early Christmas today, as the results of a psilocybin to treat depression study were released. And the results are fantastic.
This study, which used Comp 360, Compass Pathways’ (NASDAQ: CMPS) proprietary formulation of psilocybin (the active ingredient magic mushrooms) to treat Major Depressive Disorder, had fantastic results. 50% of people improved so much that they entered remission, and another 30% improved by more than 50%.
For any followers of Psychedelic Stocks, this is amazing news, and it bodes well for Compass Pathways’ phase 2b psilocybin to treat treatment-resistant depression trials. As a reminder, this trial will be the most important event for psychedelic investors, as it is the largest ever psychedelic clinical trial. It is also the furthest advanced psilocybin clinical trial, being in phase 2b.
Even if you don’t like Compass Pathways, this is very exciting news. This will benefit the entire psychedelics industry, including companies like MindMed (MNMD), Red Light Holland (TRIP), atai Life Sciences (atai) and more.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
James Twitter: @PSY_Invest
Maria’s Twitter: @PSY_Holy
Facebook: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Music: www.bensound.com
Reference: https://psilocybinalpha.com/news/open-label-study-of-comp360-psilocybin-therapy-for-depression-in-cancer-patients-demonstrates-feasibility-of-simultaneous-psilocybin-administration-in-small-groups
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#CompassPathways #Psilocybin #Psychedelics
End of content
End of content